{"slug":"nad-plus-tirzepatide","verification":{"valid":true,"entries":2,"head":"7c80d11639430167fa157575e2f124768be5395d20645fe23d61785bec481d16"},"energy":{"passes":2,"tokens_in":33686,"tokens_out":3302,"tokens_total":36988,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"7c80d11639430167fa157575e2f124768be5395d20645fe23d61785bec481d16"},"provenance":[{"ts":"2026-06-30T01:39:59.970Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: NAD Plus for Tirzepatide\nSlug: nad-plus-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"},{\"id\":\"nad-plus\",\"name\":\"NAD+\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"},{\"peptide\":\"nad-plus\",\"name\":\"NAD+\",\"section_title\":\"Why NAD+ might hel","response":"{\n  \"slug\": \"nad-plus-tirzepatide\",\n  \"title\": \"NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy\",\n  \"body\": \"## What's breaking down\\n\\nMetabolic strain from excess body weight creates ongoing mechanical overload on joints, spine, and tissues. At the same time, NAD+ levels often decline with age and metabolic stress, which can slow cellular energy production and repair processes. These two layers compound: higher body weight increases force on structures (roughly 4 pounds of compressive load per pound of body weight on the lumbar spine), while lower cellular NAD+ limits the energy available for tissue maintenance. Tirzepatide targets the weight-related mechanical layer through GLP-1 and GIP receptor activity. NAD+ supplementation is discussed for the cellular energy layer. No single compound addresses both at once.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Excess body weight sustains mechanical overload on the spine and joints, accelerating wear while repair pathways struggle to keep pace.\\n2. What Tirzepatide is studied to do: Large human trials show average weight reductions of 15–21% over 72 weeks at higher doses, with some participants reaching 20% or more loss. This directly lowers compressive forces—for example, a 10-pound loss can remove about 40 pounds of load from the lumbar spine per step.\\n3. Therefore for you: If mechanical overload from body weight forms part of the problem, Tirzepatide is discussed because it targets the load-reduction repair pathway rather than symptom masking. One observational analysis linked tirzepatide initiation to lower risk of reported joint pain (including low back, hip, and knee) and reduced NSAID or opioid prescriptions compared with another weight-loss agent.\\n\\n## Why NAD+ might help you\\n\\n1. What keeps failing: Declining NAD+ pools reduce the cell's capacity for ATP generation, mitochondrial function, and sirtuin-mediated repair, which can limit recovery from daily metabol","tokens_in":33686,"tokens_out":3302,"cost":0,"prev":"genesis","hash":"b1568eef7ee8f7878cef74b8bc8bbdea8afad2c9671cf29cbe8d01c01eb6c181"},{"ts":"2026-07-17T02:40:45.412Z","model":"owner","action":"voxel_divide","prompt":"","input":"nad-plus-tirzepatide","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b1568eef7ee8f7878cef74b8bc8bbdea8afad2c9671cf29cbe8d01c01eb6c181","hash":"7c80d11639430167fa157575e2f124768be5395d20645fe23d61785bec481d16"}]}